| Emyria Recruits 31 Therapists to Meet Growing Patient Demand | Nov 18, 2026 | Operations update | ASX |
|---|
| Change of Director's Interest Notice x 2 | Nov 17, 2026 | Ownership change notice | ASX |
|---|
| Application for quotation of securities - EMD | Nov 17, 2026 | Financing | ASX |
|---|
| Final Director's Interest Notice - J. Tooke | Nov 12, 2026 | Ownership change notice | ASX |
|---|
| Results of Annual General Meeting | Nov 12, 2026 | Meeting outcome | ASX |
|---|
| 2026 Annual General Meeting Presentation | Nov 11, 2026 | Annual report | ASX |
|---|
| Notification of cessation of securities - EMD | Nov 10, 2026 | Financing | ASX |
|---|
| September 2026 Quarterly Investor Webinar Presentation | Nov 1, 2026 | Quarterly report | ASX |
|---|
| September 2026 Quarterly Investor Update Webinar Invitation | Oct 29, 2026 | Meeting notice | ASX |
|---|
| September 2026 Quarterly Activities Report and Appendix 4C | Oct 28, 2026 | Quarterly report | ASX |
|---|
| September 2026 Quarterly Activities Report and Appendix 4C | Oct 28, 2026 | Quarterly report | ASX |
|---|
| Annual Report | Oct 8, 2026 | Annual report | ASX |
|---|
| Appendix 4G and Corporate Governance Statement | Oct 8, 2026 | Other filings | ASX |
|---|
| Letter to Shareholders - Notice of Annual General Meeting | Oct 8, 2026 | Meeting notice | ASX |
|---|
| Notice of Annual General Meeting/Proxy Form | Oct 8, 2026 | Meeting notice | ASX |
|---|
| Retirement of Non-Executive Director | Oct 8, 2026 | Management or board change | ASX |
|---|
| Webinar with Former Secretary of Veterans Affairs Dr Shulkin | Oct 5, 2026 | Other filings | ASX |
|---|
| Notification of cessation of securities - EMD | Oct 5, 2026 | Financing | ASX |
|---|
| Emyria Successfully Opens First NSW Empax Clinic | Sep 28, 2026 | Other filings | ASX |
|---|
| Application for quotation of securities - EMD | Sep 24, 2026 | Financing | ASX |
|---|
| Former US Veterans Affairs Secretary Joins Emyria | Sep 20, 2026 | Management or board change | ASX |
|---|
| Emyria Presentation at FDA Hearing | Sep 15, 2026 | Operations update | ASX |
|---|
| FDA Selects EMD to Present at Psychedelic Medicines Hearing | Sep 9, 2026 | Operations update | ASX |
|---|
| Emyria Set to Launch First NSW Clinic | Sep 7, 2026 | Other filings | ASX |
|---|
| Emyria Year End Presentation for Investor Webinar | Sep 7, 2026 | Other filings | ASX |
|---|
| Emyria Financial Year-end Update Webinar | Sep 6, 2026 | Other filings | ASX |
|---|
| Revised Securities Trading Policy | Sep 6, 2026 | Other filings | ASX |
|---|
| Appendix 4E & Annual Financial Report Year End 30 June 2026 | Aug 31, 2026 | Annual report | ASX |
|---|
| 2026 Annual General Meeting - Key Dates | Aug 31, 2026 | Meeting notice | ASX |
|---|
| Emyria Unlocks Treatment Capacity | Aug 19, 2026 | Operations update | ASX |
|---|
| Notification of cessation of securities - EMD | Aug 16, 2026 | Financing | ASX |
|---|
| Change of Registered Office and Principal Place of Business | Aug 9, 2026 | Other filings | ASX |
|---|
| June 2026 Quarterly Activities Report and Appendix 4C | Jul 28, 2026 | Quarterly report | ASX |
|---|
| June 2026 Quarterly Investor Webinar | Jul 28, 2026 | Meeting notice | ASX |
|---|
| Emyria Depression Program Shows Positive Results | Jun 23, 2026 | Results | ASX |
|---|
| Emyria Confirms NSW Workforce Ahead of Clinic Opening | Jun 21, 2026 | Other filings | ASX |
|---|
| Emyria Company Update Presentation | Jun 10, 2026 | Operations update | ASX |
|---|
| TGA Update to Accelerate Empax Therapist Recruitment | May 27, 2026 | Operations update | ASX |
|---|
| Emyria Activates First Victorian Empax Clinic | May 17, 2026 | Operations update | ASX |
|---|
| March Quarter Investor Video Presentation | May 4, 2026 | Quarterly report | ASX |
|---|
| Emyria Extends National Expansion into New South Wales | Apr 28, 2026 | Operations update | ASX |
|---|
| March 2026 Quarterly Activities Report and Appendix 4C | Apr 27, 2026 | Quarterly report | ASX |
|---|
| Emyria Launches Global Partnership Program | Apr 19, 2026 | Operations update | ASX |
|---|
| EMD Commences NSW Workforce Recruitment To Support Expansion | Apr 1, 2026 | Operations update | ASX |
|---|
| Key Milestones Achieved for First Victorian Empax Clinic | Mar 23, 2026 | Operations update | ASX |
|---|
| Appendix 4D and Half Year End Financial Report | Feb 26, 2026 | Interim report | ASX |
|---|
| Medibank Expands Funding to Emyria's Victorian Clinic | Feb 15, 2026 | Operations update | ASX |
|---|
| Emyria's PTSD Program Delivers Lasting Recovery | Feb 1, 2026 | Results | ASX |
|---|
| December 2025 Quarterly Activities Report and Appendix 4C | Jan 27, 2026 | Quarterly report | ASX |
|---|
| Victorian Clinic Confirmed, National Rollout Proceeding | Dec 15, 2025 | Operations update | ASX |
|---|
| Emyria's Perth Expansion a Template for East Coast Rollout | Dec 10, 2025 | Operations update | ASX |
|---|
| Institutional Placement Accelerates EMD National Expansion | Nov 19, 2025 | Financing | ASX |
|---|
| Trading Halt | Nov 17, 2025 | Trading halt or suspension | ASX |
|---|
| September 2025 Quarterly Activities Report and Appendix 4C | Oct 26, 2025 | Quarterly report | ASX |
|---|
| Medibank Expands Funding Agreement to Emyria Brisbane Clinic | Oct 14, 2025 | Operations update | ASX |
|---|
| Emyria Secures Medibank Funding for Depression Care Program | Sep 22, 2025 | Operations update | ASX |
|---|
| Appendix 4E & Annual Report for the Year Ended 30 June 2025 | Aug 27, 2025 | Annual report | ASX |
|---|
| Emyria to Expand Perth Clinic to Meet Growing Demand | Aug 26, 2025 | Other filings | ASX |
|---|
| Emyria Commences National Expansion with Avive in Brisbane | Jul 28, 2025 | Operations update | ASX |
|---|
| June 2025 Quarterly Activities Report and Appendix 4C | Jul 28, 2025 | Quarterly report | ASX |
|---|
| Medibank to Fund Emyria's PTSD Program at Perth Clinic | Jun 18, 2025 | Operations update | ASX |
|---|
| PTSD Gains Sustained at 6m Follow-Up, MOU Signed with ANU | May 27, 2025 | Results | ASX |
|---|
| March 2025 Quarterly Activities Report and Appendix 4C | Apr 28, 2025 | Quarterly report | ASX |
|---|
| Emyria Opens New Empax Centre to Meet Demand and Payer Needs | Apr 13, 2025 | Operations update | ASX |
|---|
| Emyria Reports Promising 3-Month PTSD Treatment Results | Feb 3, 2025 | Results | ASX |
|---|
| December 2024 Quarterly Activities Report and Appendix 4C | Jan 31, 2025 | Quarterly report | ASX |
|---|
| Leadership Updates | Jan 21, 2025 | Management or board change | ASX |
|---|
| Emyria Secures $2.525M in Strongly Supported Placement | Nov 26, 2024 | Financing | ASX |
|---|
| Response to ASX Price Query | Nov 12, 2024 | Explanation request | ASX |
|---|
| Emyria & UWA Partner to License Novel Serotonin Therapies | Oct 30, 2024 | Operations update | ASX |
|---|
| September 2024 Quarterly Activities Report and Appendix 4C | Oct 29, 2024 | Quarterly report | ASX |
|---|
| Emyria Gains Ethics Endorsement for Psilocybin Program | Oct 27, 2024 | Operations update | ASX |
|---|
| Emyria Shares Interim Success in PTSD Treatment Program | Sep 2, 2024 | Results | ASX |
|---|
| Appendix 4E & Annual Report for the Year Ended 30 June 2024 | Aug 30, 2024 | Annual report | ASX |
|---|
| June 2024 Quarterly Activities Report and Appendix 4C | Jul 29, 2024 | Quarterly report | ASX |
|---|
| Emyria, UWA Secure $499K Grant for MDMA Analogue Program | Jun 30, 2024 | Other filings | ASX |
|---|
| Empax Centre Selected As Key Site In Global PTSD Study | Jun 19, 2024 | Operations update | ASX |
|---|
| March 2024 Quarterly Activities Report and Appendix 4C | Apr 25, 2024 | Quarterly report | ASX |
|---|
| Emyria Receives Bids of $2.3M to Expand Clinical Services | Apr 23, 2024 | Financing | ASX |
|---|
| Emyria Opens Empax Centre to Advance Mental Health Care | Apr 9, 2024 | Operations update | ASX |
|---|
| Emyria Expands Specialist AP Team - First Female for MDMA-AT | Apr 4, 2024 | Operations update | ASX |
|---|
| Emyria, Reach Wellness Enter MDMA-AT Research Agreement | Apr 2, 2024 | Operations update | ASX |
|---|
| Response to ASX Aware Query | Mar 12, 2024 | Explanation request | ASX |
|---|
| December 2023 Quarterly Activities Report and Appendix 4C | Jan 30, 2024 | Quarterly report | ASX |
|---|
| Emyria Receives $2.5M R&D Tax Incentive Refund | Jan 14, 2024 | Results | ASX |
|---|
| Emyria Specialist Granted Authorised Prescriber Status | Jan 9, 2024 | Operations update | ASX |
|---|
| Board Changes and Executive Restructuring | Nov 12, 2023 | Management or board change | ASX |
|---|
| Emyria Secures Ethics Endorsement for MDMA AP Application | Oct 29, 2023 | Operations update | ASX |
|---|
| September 2023 Quarterly Activities Report and Appendix 4C | Oct 25, 2023 | Quarterly report | ASX |
|---|
| Health Canada Approval Received for MDMA Import | Oct 18, 2023 | Operations update | ASX |
|---|
| Emyria's Clinic Achieves Key MDMA-AT Dosing Milestone | Oct 8, 2023 | Operations update | ASX |
|---|
| Completion of Entitlement Offer | Oct 5, 2023 | Financing | ASX |
|---|
| Emyria Secures Local MDMA to Start PTSD Trial Dosing | Sep 20, 2023 | Other filings | ASX |
|---|
| Emyria Completes Acquisition of the Pax Centre | Sep 13, 2023 | Acquisition or disposal | ASX |
|---|
| Strategic Update & Entitlement Offer Presentation | Sep 5, 2023 | Financing | ASX |
|---|
| Prospectus | Sep 5, 2023 | Offer document | ASX |
|---|
| Emyria Gets $2M Bids, Sets $3.1M Entitlement Offer | Sep 4, 2023 | Financing | ASX |
|---|
| Appendix 4E Preliminary Financial Report | Aug 30, 2023 | Results | ASX |
|---|
| Emyria Launches Ketamine-Assisted Therapy Program | Aug 7, 2023 | Other filings | ASX |
|---|
| June 2023 Quarterly Activities Report and Appendix 4C | Jul 31, 2023 | Quarterly report | ASX |
|---|
| Emyria Recruits First Patient MDMA-Assisted Therapy Trial | Jul 9, 2023 | Other filings | ASX |
|---|
| Presentation - Pax Acquisition and Company Update | Jul 5, 2023 | Acquisition or disposal | ASX |
|---|
| Pax Centre Acquisition to Advance Psychedelic Therapies | Jul 3, 2023 | Acquisition or disposal | ASX |
|---|
| Emyria Receives Ethics Approval for MDMA-assisted Therapy | Jun 7, 2023 | Other filings | ASX |
|---|
| Emyria Completes $2.5m Placement | May 1, 2023 | Financing | ASX |
|---|
| March 2023 Quarterly Activities Report and Appendix 4C | Apr 28, 2023 | Quarterly report | ASX |
|---|
| Emyria Unveils Highest Potency CBD Capsule for FDA Pathway | Apr 23, 2023 | Other filings | ASX |
|---|
| Emyria to Develop Psilocybin Therapy Care Model | Apr 17, 2023 | Other filings | ASX |
|---|
| Emyria, Aspen Sign Binding Commercial Term Sheet for EMD-RX5 | Apr 3, 2023 | Other filings | ASX |
|---|
| Strong Recruitment for EMD-RX5 Phase 3 Trial | Mar 22, 2023 | Other filings | ASX |
|---|
| Emyria Grows MDMA Asset for Neuro & Mental Health Therapy | Mar 19, 2023 | Other filings | ASX |
|---|
| Emyria partners with PAX Centre for MDMA-assisted therapy | Mar 6, 2023 | Other filings | ASX |
|---|
| Half Yearly Report and Accounts | Feb 26, 2023 | Interim report | ASX |
|---|
| Emyria secures clinical-grade MDMA supply for Aust patients | Feb 12, 2023 | Other filings | ASX |
|---|
| Emyria expands MDMA programs following landmark TGA decision | Feb 5, 2023 | Other filings | ASX |
|---|
| Appendix 4C - Quarterly | Jan 30, 2023 | Quarterly report | ASX |
|---|
| First dosing commenced for pivotal EMD-RX5 Phase 3 trial | Jan 29, 2023 | Other filings | ASX |
|---|
| Emyria receives $2.1M R&D tax incentive refund | Jan 11, 2023 | Other filings | ASX |
|---|
| Emyria accepted into National Institutes of Health Program | Nov 27, 2022 | Other filings | ASX |
|---|
| Placement completion and secondary trading notice | Nov 22, 2022 | Financing | ASX |
|---|
| Emyria completes $3m placement | Oct 30, 2022 | Financing | ASX |
|---|
| Emyria and UWA expand unique MDMA-inspired analogue library | Oct 17, 2022 | Other filings | ASX |
|---|
| Emyria expands clinical sites for EMD-RX5 Phase 3 trial | Sep 25, 2022 | Other filings | ASX |
|---|
| Emyria commences US preclinical program for MDMA library | Sep 19, 2022 | Other filings | ASX |
|---|
| Appendix 4E and Annual Report | Aug 29, 2022 | Annual report | ASX |
|---|
| Positive results received for Emyrias MDMA-inspired program | Aug 17, 2022 | Other filings | ASX |
|---|
| Emyria receives ethics approval for EMD-RX5 Phase 3 trial | Aug 16, 2022 | Other filings | ASX |
|---|
| Preclinical studies initiated for MDMA-inspired analogues | Aug 4, 2022 | Other filings | ASX |
|---|
| Emyria expands drug candidate library inspired by MDMA | Jul 17, 2022 | Other filings | ASX |
|---|
| Emyria expands MDMA analogue program with UWA | May 31, 2022 | Other filings | ASX |
|---|
| EMD-RX5 demonstrates excellent safety and bioavailability | May 24, 2022 | Other filings | ASX |
|---|
| Further positive MDMA analogue screening results received | May 9, 2022 | Other filings | ASX |
|---|
| Emyria launches second ultra-pure CBD capsule | Mar 16, 2022 | Other filings | ASX |
|---|
| Recruitment commenced for EMD-RX5 Phase 1 Study | Mar 8, 2022 | Other filings | ASX |
|---|
| Ethics approval received for EMD-RX5 Phase 1 Study | Mar 3, 2022 | Other filings | ASX |
|---|
| Emyria grows its novel MDMA-analogue library | Feb 21, 2022 | Other filings | ASX |
|---|
| Phase 1 trial commences Q1, 2022 for Emyrias ultra-pure CBD | Jan 19, 2022 | Other filings | ASX |
|---|
| Emyria adds wearables to psychedelic-assisted therapy trials | Dec 19, 2021 | Other filings | ASX |
|---|
| Pause in Trading | Dec 15, 2021 | Trading halt or suspension | ASX |
|---|
| Positive animal data for Emyrias ultra-pure CBD capsule | Dec 14, 2021 | Other filings | ASX |
|---|
| Positive initial MDMA-analogue screening results | Dec 7, 2021 | Other filings | ASX |
|---|
| Emyria receives $1,162,000 R&D Tax Incentive Refund | Nov 23, 2021 | Other filings | ASX |
|---|
| Emyria Welcomes Tattarang as Strategic Investor | Nov 21, 2021 | Other filings | ASX |
|---|
| MDMA Analogue Development Milestone | Oct 18, 2021 | Other filings | ASX |
|---|
| Emyria selected to join Palantirs Foundry Builders Program | Oct 6, 2021 | Other filings | ASX |
|---|
| Novel MDMA Analogue Screening Program Advanced | Sep 21, 2021 | Other filings | ASX |
|---|
| Emyria Expands Psychiatry Advisory for Psychedelics and MDMA | Sep 15, 2021 | Other filings | ASX |
|---|
| MDMA-analogues Show Promise for Parkinsons Disease | Aug 31, 2021 | Other filings | ASX |
|---|
| Emyria Engages Calvert Labs for Preclinical CBD studies | Aug 26, 2021 | Other filings | ASX |
|---|
| Emyria Appoints Expert Neuropharmacologist for MDMA Program | Aug 19, 2021 | Other filings | ASX |
|---|
| Emyria Executes Pure CBD Agreement with AltaSciences | Aug 12, 2021 | Other filings | ASX |
|---|
| Emyria to Develop Novel Psychedelics Pipeline with UWA | Aug 4, 2021 | Other filings | ASX |
|---|
| Emyria Advances EMD-004 Program Towards Registration | Jun 14, 2021 | Other filings | ASX |
|---|
| Emyria Data Validated, Care Model Reduces Opioids | Jun 6, 2021 | Other filings | ASX |
|---|
| Emyria Obtains TGA Approval for Medical Grade Monitoring App | May 12, 2021 | Other filings | ASX |
|---|
| Emyria and MMA launch MDMA-assisted therapy program for PTSD | May 4, 2021 | Other filings | ASX |
|---|
| $5m Placement for Drug Registration and Treatment Pipeline | Apr 21, 2021 | Financing | ASX |
|---|
| Emyria and Cann Partner to Register CBD Product | Mar 28, 2021 | Other filings | ASX |
|---|
| Emyria Adds Second Clinical Site in Perth | Mar 1, 2021 | Other filings | ASX |
|---|
| Emyria adds second Emerald Clinic in Melbourne | Feb 9, 2021 | Other filings | ASX |
|---|
| Emyria wins digital health monitoring grant with UWA | Feb 4, 2021 | Other filings | ASX |
|---|
| FDA Position on RWE to Guide Registration | Jan 26, 2021 | Other filings | ASX |
|---|
| Emyria Pursuing Registration of EMD-003 in CY2021 | Jan 4, 2021 | Other filings | ASX |
|---|
| Emyria to Benefit from Final TGA Ruling on CBD Medicines | Dec 15, 2020 | Other filings | ASX |
|---|
| Emyria Sees Strong Interest in IBS Study | Dec 3, 2020 | Other filings | ASX |
|---|
| Emyria Launches Drug Development Program Based on RWE | Nov 24, 2020 | Other filings | ASX |
|---|
| Emyria Partners with Thought Leaders in Psychedelic Therapy | Nov 18, 2020 | Other filings | ASX |
|---|
| Emyria Enters Data Deal with ZLD to Support Autism Trial | Nov 8, 2020 | Other filings | ASX |
|---|
| Webinar on Global Partnership with Sapphire Medical Clinics | Oct 21, 2020 | Other filings | ASX |
|---|
| Emyria Signs Real-World Data Agreement with Zelira | Sep 29, 2020 | Other filings | ASX |
|---|
| Preliminary Final Report and Full Year Statutory Accounts | Aug 31, 2020 | Annual report | ASX |
|---|
| Emerald Clinics Successfully Raises $2.2m in Placement | Aug 28, 2020 | Financing | ASX |
|---|
| Record Appointments International Expansion and Name Change | Aug 13, 2020 | Other filings | ASX |
|---|
| Emerald Signs RWE Contract with Canopy Growth UK Company | Aug 9, 2020 | Other filings | ASX |
|---|
| EMDs Digital Health Platform Expands with New Technology | Jun 21, 2020 | Other filings | ASX |
|---|
| EMD Program Manager of National Clinical Data and Analytics | May 11, 2020 | Other filings | ASX |
|---|